Skip to Content
Søg Menu

RWD for mRCC: Cabozantinib + Nivolumab Shows Comparable Results to CheckMate 9ER

Cabozantinib + Nivolumab redefined first-line treatment in mRCC after showing significant benefit over sunitinib in the phase III CheckMate 9ER study. At ASCO GU, Martin Zarba presents new real-world data exploring how these results translate into clinical practice.
Martin Zarba

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Fernando De Moura

ASCO GU 2026: Intensifying Neoadjuvant Androgen Blockade Before Prostatectomy in High-Risk Prostate Cancer

/ Fernando de Moura
ASCOGU26Prostatacancer Play the Video 4:11

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrecancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrecancer
Sylvie Negrier

Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

/ Sylvie Negrier
ASCOGU25Nyrecancer Play the Video 04:15

Dansk studie afslører fordobling af nyrecancer-tilfælde

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Nyrecancer

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
ESMO24ProstatacancerNyrecancerBlærecancer

Rechallenge of IO/TKI in Second-Line After IO/TKI in First-Line Will Not Add Any Benefits

/ Sofie Pohl
Nyrecancer
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
ESMO24ProstatacancerNyrecancerBlærecancer Play the Video 4:25
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Nyrecancer Play the Video 04:33
Back to top